Evidence Level:Sensitive: D – Preclinical
Title:
ABBV-011, A Novel, Calicheamicin-Based Antibody–Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors
Excerpt:We next tested the antitumor activity of ABBV-011 using PDX models of SCLC...A single dose of ABBV-011 resulted in significant, and dose-dependent tumor regression in LU64, a SEZ6-positive PDX line…
DOI:https://doi.org/10.1158/1535-7163.MCT-21-0851